Altimmune, Inc. Common Stock

The alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected t...

Altimmune announced 48-week data from its IMPACT Phase 2b trial showing that pemvidutide, a glucagon/GLP-1 dual receptor agonist, significantly reduced triglycerides (-23.7%), total cholesterol (-15.4%), and improved weight loss (7.5%), blood pressure, and waist circumference in MASH patients. The drug demonstrated a favorable safety profile with...

Altimmune closed a $225 million oversubscribed public offering led by Deep Track Capital, with participation from TCGX, Viking Global Investors, and RA Capital Management. The company will use proceeds to fund its Phase 3 MASH trial expected to initiate in H2 2026 and provide cash runway through the anticipated 52-week data readout. Pemvidutide, ...

Altimmune, Inc. (Nasdaq: ALT) announced the pricing of an underwritten public offering of common stock and warrants expected to raise approximately $225 million in gross proceeds. The offering consists of 64.25 million shares of common stock with accompanying warrants at $3.00 per share, plus optional pre-funded warrants. The company plans to use...

Avaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes progra...